Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.

@article{Pavie2011EfficacyAS,
  title={Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.},
  author={Juliette Pavie and Raphael Porcher and Carlo Torti and Jos{\'e} Luis Jasso Medrano and Antonella Castagna and Nadia Valin and Stefano Rusconi and Adriana Ammassari and Jade Ghosn and Constance Delaugerre and Jean-Michel Molina},
  journal={The Journal of antimicrobial chemotherapy},
  year={2011},
  volume={66 10},
  pages={2372-8}
}
BACKGROUND Limited data are available on the use of unboosted atazanavir in combination with nucleoside reverse transcriptase inhibitors (NRTIs) in treatment-experienced HIV-infected patients. METHODS We conducted a multicentre, retrospective study among patients with plasma HIV-1 RNA levels <50 copies/mL under antiretroviral therapy who switched to unboosted atazanavir + NRTIs between January 2002 and December 2008. Virological failure during follow-up was defined as a confirmed plasma HIV-1… CONTINUE READING
9 Citations
23 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Long-term outcomes of patients receiving unboosted atazanavir in combination with TDF

  • M Hull, S Guillemi, M Harris
  • Abstracts of the 18th Conference on Retroviruses…
  • 2011

Race differences in the efficacy of initial ART on HIV infection in randomized trials undertaken by ACTG

  • H Ribaudo, K Smith, G Robbins
  • Abstracts of the 18th Conference on Retroviruses…
  • 2011

Similar Papers

Loading similar papers…